Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OBIO vs ICCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICCC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–2 Matrix Metrics)

ICCC Overall Winner 6-Pillar Tally: OBIO 1 – 5 ICCC Matrix Metrics: OBIO 2 – 7 ICCC

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Orchestra BioMed Holdings, Inc. (OBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OBIO carries a Unified Composite Score of 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs ICCC
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 82% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 69
RSI-14: 69.2 · SMA20: $5.93 · SMA50: $5.90
ICCC NASDAQ Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.24β · 46% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13

6-Pillar Scorecard Institutional Category Breakdown (OBIO 1 – 5 ICCC)

Columns: Metric · OBIO · ICCC
1. Valuation Multiples ICCC
Forward P/E N/M N/M
Trailing P/E N/M 56.6x
PEG Ratio N/M N/M
EV / Revenue 18.6x 1.6x
2. Growth & Scale ICCC
Revenue Growth (YoY) -89.4% +11.5%
Earnings Growth (YoY) +0.0% +259.9%
TTM Revenue (USD) $31M $67M
Market Cap $570.6M $97.7M
3. Profitability & Quality ICCC
Gross Margin 99.6% 40.3%
Operating Margin -195.4% 15.2%
Net Profit Margin -182.5% 2.6%
Return on Equity (ROE) -182.3% 2.6%
4. Balance Sheet & Cash Flow ICCC
Cash Generation (TTM) -$64M $7.4M
Cash Flow Margin N/A 11.0%
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $13M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 70.8% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ICCC
OpEx & R&D Intensity N/A 25.1% of Rev ($17M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (2) vs ICCC (7)
Institutional Metric OBIO ICCC Criterion Row Edge
Market Capitalization
Scale
$570.6M $97.7M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M 56.6x Lower Multiple ICCC
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-89.4% +11.5% Higher Growth ICCC
Operating Margin (TTM)
Profitability
-195.4% 15.2% Higher Margin ICCC
Net Profit Margin
Profitability
-182.5% 2.6% Higher Margin ICCC
Return on Equity (ROE)
Capital Efficiency
-182.3% 2.6% Higher ROE ICCC
52-Week Range Position
Momentum
92% ($3–$7) 91% ($5–$12) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.15β · 82% Vol 0.24β · 46% Vol Lower Realized Risk ICCC
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 43.8 / 100 (HOLD) Higher Composite ICCC
Trailing 12M Revenue (USD)
Operating Scale
$31M $67M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% 40.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.6x EV/Rev N/M PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) $7.4M ($13M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +24.41 pp
OBIO: +30.64% · ICCC: +6.23%
3M Horizon OBIO +8.79 pp
OBIO: +25.8% · ICCC: +17.01%
6M Horizon OBIO +63.65 pp
OBIO: +78.89% · ICCC: +15.24%
1Y Horizon ICCC +18.43 pp
OBIO: +70.33% · ICCC: +88.76%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue ICCC Revenue OBIO Op. Margin ICCC Op. Margin Margin Leader
FY2018 N/A $10M N/A -13.2% ICCC
FY2019 N/A $10M N/A -7.0% ICCC
FY2020 N/A $20M N/A -9.0% ICCC
FY2021 N/A $20M N/A 1.3% ICCC
FY2022 $0M $20M -924.3% -12.4% ICCC
FY2023 $0M $20M -1866.2% -32.9% ICCC
FY2024 $0M $30M -2437.5% -6.2% ICCC
FY2025 $30M $30M -154.7% 6.0% ICCC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO BREAKOUT
32d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ICCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ICCC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($17M)
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs ICCC Key Questions & Quantitative Answers

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Orchestra BioMed Holdings, Inc. (OBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OBIO carries a Unified Composite Score of 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin). Technically, OBIO sits in a Markup phase (RSI 69.2, BREAKOUT options structure) and ICCC sits in a Markup phase (RSI 67.5, UNCLASSIFIED options structure).

ICCC leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with ICCC at +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OBIO cumulative revenue shifted N/A while ICCC shifted +200.0%. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($17M) (0 disclosures) for ICCC.

ICCC screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus ICCC (2.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 82% Vol realized risk). By comparison, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.